Axovant Sciences Ltd (AXON) Earns “Buy” Rating from Oppenheimer Holdings Inc.
Several other brokerages have also recently commented on AXON. Robert W. Baird reiterated an outperform rating and set a $29.00 target price on shares of Axovant Sciences in a research report on Friday, November 25th. Zacks Investment Research upgraded shares of Axovant Sciences from a sell rating to a hold rating in a research report on Thursday, March 9th. Piper Jaffray Companies set a $32.00 price objective on shares of Axovant Sciences and gave the company a buy rating in a research report on Sunday, December 18th. Laidlaw initiated coverage on shares of Axovant Sciences in a research report on Tuesday, December 20th. They issued a sell rating and a $7.50 price objective for the company. Finally, Cowen and Company initiated coverage on shares of Axovant Sciences in a research report on Friday, February 3rd. They issued an outperform rating and a $22.00 price objective for the company. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have given a buy rating to the company. The company has a consensus rating of Buy and a consensus price target of $27.04.
Axovant Sciences (NYSE:AXON) opened at 21.87 on Wednesday. The company’s 50-day moving average price is $15.88 and its 200-day moving average price is $13.65. The firm’s market cap is $2.17 billion. Axovant Sciences has a one year low of $10.69 and a one year high of $23.58.
Axovant Sciences (NYSE:AXON) last issued its earnings results on Tuesday, February 14th. The biotechnology company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.45) by $0.03. On average, analysts anticipate that Axovant Sciences will post ($1.81) EPS for the current year.
WARNING: “Axovant Sciences Ltd (AXON) Earns “Buy” Rating from Oppenheimer Holdings Inc.” was published by Marea Informative and is the property of of Marea Informative. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright and trademark law. The legal version of this report can be viewed at http://www.mareainformativa.com/axovant-ciencias-axon-comprar-reafirman-calificacion-de-oppenheimer-holdings-inc/108226/.
In other Axovant Sciences news, insider David Hung acquired 539,375 shares of Axovant Sciences stock in a transaction dated Monday, April 17th. The stock was bought at an average cost of $18.54 per share, for a total transaction of $10,000,012.50. Following the purchase, the insider now directly owns 539,375 shares in the company, valued at approximately $10,000,012.50. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director W Anthony Vernon acquired 53,937 shares of Axovant Sciences stock in a transaction dated Monday, April 17th. The shares were acquired at an average price of $18.54 per share, with a total value of $999,991.98. Following the completion of the purchase, the director now owns 53,937 shares in the company, valued at $999,991.98. The disclosure for this purchase can be found here. 3.10% of the stock is currently owned by corporate insiders.
A number of large investors have recently modified their holdings of AXON. Janus Capital Management LLC increased its stake in shares of Axovant Sciences by 5.9% in the fourth quarter. Janus Capital Management LLC now owns 4,679,224 shares of the biotechnology company’s stock valued at $58,121,000 after buying an additional 261,097 shares during the period. Highbridge Capital Management LLC purchased a new stake in shares of Axovant Sciences during the third quarter valued at about $1,057,000. Deltec Asset Management LLC increased its stake in shares of Axovant Sciences by 614.3% in the third quarter. Deltec Asset Management LLC now owns 75,000 shares of the biotechnology company’s stock valued at $1,050,000 after buying an additional 64,500 shares during the period. Artal Group S.A. boosted its position in Axovant Sciences by 20.0% in the fourth quarter. Artal Group S.A. now owns 300,000 shares of the biotechnology company’s stock valued at $3,726,000 after buying an additional 50,000 shares in the last quarter. Finally, Franklin Resources Inc. boosted its position in Axovant Sciences by 2.7% in the fourth quarter. Franklin Resources Inc. now owns 1,612,682 shares of the biotechnology company’s stock valued at $20,030,000 after buying an additional 42,000 shares in the last quarter.
Axovant Sciences Company Profile
Axovant Sciences Ltd. is a Bermuda-based clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
Receive News & Stock Ratings for Axovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd and related stocks with our FREE daily email newsletter.